Jeffrey B. Kindler
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Perrigo valuation seen as cheap but burdened by high debt. A recent Seeking Alpha article notes that Perrigo's shares appear cheap compared with peers. The piece highlights that the company carries a sizable debt load, which could limit financial flexibility. This contrast may lead investors to weigh the low valuation against the debt risk when evaluating the company.
Transaction History
| PGEN | ▼ Sell | Open Market | 185,000 | $1.4M | 8/26/2026 | View on chart |
| PRAX | ▲ Buy | Grant | 1,371 | $0 | 6/10/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 71,839 | — | 3/13/2026 | View on chart |
| PGEN | ▲ Buy | Grant | 19,658 | $69K | 3/10/2026 | View on chart |
| PRAX | ▲ Buy | Grant | 688 | $0 | 2/6/2026 | View on chart |
| PRAX | ▲ Buy | Grant | 478 | $0 | 2/6/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 235,467 | $856K | 12/12/2025 | View on chart |
| PGEN | ▼ Sell | Open Market | 106,837 | $361K | 9/30/2025 | View on chart |
| PGEN | ▼ Sell | Open Market | 67,523 | $243K | 9/29/2025 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 9,904 | $258K | 5/14/2025 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 4,754 | $124K | 5/14/2025 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 87,412 | — | 3/14/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 39,655 | $69K | 3/13/2025 | View on chart |
| PRGO | ▼ Sell | Open Market | 17,598 | $497K | 12/9/2024 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 8,764 | $265K | 5/15/2024 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 4,207 | $127K | 5/15/2024 | View on chart |
| PGEN | ▲ Buy | Grant | 48,251 | $69K | 3/14/2024 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 106,837 | — | 3/9/2024 | View on chart |
| PGEN | ▼ Sell | Open Market | 96,686 | $136K | 12/28/2023 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 7,778 | $256K | 5/17/2023 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 3,734 | $123K | 5/17/2023 | View on chart |
| PGEN | ▲ Buy | Grant | 58,974 | $69K | 3/9/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 61,576 | — | 2/22/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 50,000 | $115K | 8/11/2022 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 6,599 | $255K | 5/17/2022 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 3,168 | $122K | 5/17/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 16,212 | — | 3/25/2022 | View on chart |
| PGEN | ▲ Buy | Grant | 33,990 | $69K | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog
Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.